N-异丙基吡咯烷酮 | 3772-26-7

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: N-异丙基吡咯烷酮
• 中文别名: N-异丙基-2-吡咯烷酮
• 英文名称: N-isopropyl-2-pyrrolidone
• 英文别名: N-(isopropyl)-2-pyrrolidone；1-isopropyl-pyrrolidin-2-one；1-isopropylpyrrolidin-2-one；N-isopropyl-2-pyrrolidinone；1-isopropyl-2-pyrrolidone；1-Isopropyl-pyrrolidin-2-on；2-Pyrrolidinone, 1-(1-methylethyl)-；1-propan-2-ylpyrrolidin-2-one
• CAS: 3772-26-7
• 化学式: C₇H₁₃NO
• mdl: MFCD00015398
• 分子量: 127.186
• InChiKey: GHELJWBGTIKZQW-UHFFFAOYSA-N

物化性质

• 熔点：
  18°C
• 沸点：
  218℃
• 密度：
  0.990
• 闪点：
  31℃

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933790090
• 包装等级：
  III
• 危险类别：
  6.1
• 危险性防范说明：
  P260,P201,P264,P280,P308+P313,P304+P340+P312
• 危险品运输编号：
  2810
• 危险性描述：
  H315,H319,H373,H335,H360,H336
• 储存条件：
  室温

制备方法与用途

用途：可用作香料、合成萘普生及计划生育药物的起始原料。

反应信息

• 作为反应物：
  描述：

  N-异丙基吡咯烷酮 在 2-溴-1,3,5-三甲基苯 、 叔丁基锂 、 六氯乙烷 作用下， 以 四氢呋喃 、 正戊烷 为溶剂， 反应 1.5h， 以70%的产率得到3-chloro-1-isopropylpyrrolidin-2-one
  参考文献：
  名称：

  Translocator protein ligands based on N -methyl-(quinolin-4-yl)oxypropanamides with properties suitable for PET radioligand development

  摘要：

  Modifications to an N-methyl-(quinolin-4-yl)oxypropanamide scaffold were explored to discover leads for developing new radioligands for PET imaging of brain TSPO (translocator protein), a biomarker of neuroinfiammation. Whereas contraction of the quinolinyl portion of the scaffold or cyclization of the tertiary amido group abolished high TSPO affinity, insertion of an extra nitrogen atom into the 2-arylquinolinyl portion was effective in retaining sub-nanomolar affinity for rat TSPO, while also decreasing lipophilicity to within the moderate range deemed preferable for a PET radioligand. Replacement of a phenyl group on the amido nitrogen with an isopropyl group was similarly effective. Among others, compound 20 (N-methyl-N-phenyl-2-[2-(pyridin-2-yl)-1,8-naphthyridin-4-yloxy]propanamide) appears especially appealing for PET radioligand development, based on high selectivity and high affinity (K-i = 0.5 nM) for rat TSPO, moderate lipophilicity (logD = 2.48), and demonstrated amenability to labeling with carbon-11. Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2016.08.046
• 作为产物：
  描述：

  1-异丙基-1,5-二氢-2H-吡咯-2-酮 在 RuCl2(1,3-dimesityl-imidazolidin-2-yl)(PCy3)(=CHPh) 氢气 作用下， 以 1,2-二氯乙烷 为溶剂， 70.0 ℃ 、689.49 kPa 条件下， 以68 mg的产率得到N-异丙基吡咯烷酮
  参考文献：
  名称：

  串联催化：烯烃复分解、氢化和氢转移与单组分 Ru 配合物的顺序介导

  摘要：

  有机金属催化剂传统上被设计和优化以介导单一反应。然而，对方便有效的合成过程日益增长的需求需要开发能够直接或通过简单修饰催化多种机械不同反应的有机金属试剂。虽然 Ru 配合物 (PCy_3)_2Cl_2Ru= CHPh (1) 在烯烃复分解中得到了广泛的应用，但最近它也被证明是一种有效的预催化剂，用于介导自由基加成和加氢反应。我们最近证明了所有三个反应都可以串联进行，以提供明确定义的嵌段共聚物。在此，我们报告复合体 1，或其更活跃的衍生物 2，也可用于介导各种其他催化氢化反应，包括区域特异性酮和烯烃还原、酮的转移氢化和醇的脱氢氧化。此外，我们展示了各种用于快速构建小分子的“一锅”串联复分解加氢程序，包括 (R)-(-)-Muscone。

  DOI：

  10.1021/ja016431e

文献信息

• BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE
  申请人：Arvinas Operations, Inc.

  公开号：US20190300521A1

  公开（公告）日：2019-10-03

  The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand that binds to the Von Hippel-Lindau E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为SMARCA2或BRM（靶蛋白）的调节剂具有实用性。具体而言，本公开涉及包含一端结合Von Hippel-Lindau E3泛素连接酶的配体，另一端结合靶蛋白的双功能化合物，使得靶蛋白与泛素连接酶靠近以实现靶蛋白的降解（和抑制）。本公开展示了与靶蛋白降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由靶蛋白聚集或积累导致的疾病或紊乱。
• TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE
  申请人：Arvinas, Inc.

  公开号：US20180125821A1

  公开（公告）日：2018-05-10

  The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为tau蛋白的调节剂具有实用性。具体而言，本公开涉及含有一端结合到E3泛素连接酶的VHL或cereblon配体，另一端结合到tau蛋白的双功能化合物，使得tau蛋白与泛素连接酶靠近，以实现tau蛋白的降解（和抑制）。本公开展示了与tau蛋白降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由tau蛋白聚集或积累导致的疾病或紊乱。
• COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES
  申请人：Arvinas, Inc.

  公开号：US20190151295A1

  公开（公告）日：2019-05-23

  The present disclosure relates to bifunctional compounds, which find utility as modulators of Interleukin-1 Receptor-Associated Kinase 4 (IRAK-4); the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hppel-Lindau, cereblon, ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为白细胞介素-1受体相关激酶4（IRAK-4；目标蛋白）的调节剂具有实用性。具体而言，本公开涉及包含一端结合E3泛素连接酶的Von Hppel-Lindau、cereblon配体的双功能化合物，另一端结合目标蛋白的部分，使得目标蛋白靠近泛素连接酶以实现目标蛋白的降解（和抑制）。本公开展示了与目标蛋白的降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由目标蛋白聚集或积累导致的疾病或紊乱。
• CONJUGATES OF CEREBLON BINDING COMPOUNDS AND G12C MUTANT KRAS, HRAS OR NRAS PROTEIN MODULATING COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Araxes Pharma LLC

  公开号：US20180015087A1

  公开（公告）日：2018-01-18

  Conjugates of a cereblon-binding compound and compounds having modulatory activity against G12C mutant KRAS, HRAS or NRAS G12C proteins are provided. Methods associated with preparation and use of such conjugates, pharmaceutical compositions comprising such conjugates and methods to modulate the activity of G12C mutant KRAS, HRAS or NRAS G12C proteins for treatment of disorders, such as cancer, are also provided.

  提供了与谷氨酰脑结合化合物和具有调节活性对抗G12C突变KRAS、HRAS或NRAS G12C蛋白的化合物的共轭物。还提供了与制备和使用这种共轭物相关的方法，包括含有这种共轭物的药物组合物以及调节G12C突变KRAS、HRAS或NRAS G12C蛋白活性的方法，用于治疗癌症等疾病。
• THIOARYL SUBSTITUTED INHIBITORS OF ZINC PROTEASES AND THEIR USE
  申请人：Rossello Armando

  公开号：US20090239829A1

  公开（公告）日：2009-09-24

  There are described compounds having the general formula (I) below and their pharmaceutically acceptable salts thereof, wherein E, X, m, q, R 1 , R 2 , n and ZBG have the meanings reported in the description useful, in therapy, as inhibitors of zinc metalloproteinases.

  描述了具有下面一般式（I）的化合物及其药学上可接受的盐，其中E、X、m、q、R1、R2、n和ZBG的含义如描述中所述，在治疗中作为锌金属蛋白酶的抑制剂。